Helus Pharma announced the immediate departure of CEO Michael Cola at the Board's request, with co-founder and Executive Chairman Eric So resuming the role of Interim CEO while a permanent successor is sought.
Key takeaways
CEO Michael Cola stepped down effective immediately at the request of the Board of Directors.
Co-founder and Executive Chairman Eric So was appointed Interim CEO effective immediately, bringing continuity as he previously held the interim role.
The Board has initiated a search process to identify a permanent Chief Executive Officer.
The company's clinical priorities remain focused on the upcoming topline data readout from the APPROACH trial of HLP003 expected in the fourth quarter.